DYAI Dyadic International Inc.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Date	Price Target	Rating	Analyst
7/18/2022		Buy → Neutral	Dawson James
12/17/2021	$7.00	Buy	HC Wainwright & Co.

Dyadic International Inc.

Peers

Recent Analyst Ratings for Dyadic International Inc.

Dyadic International Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by President and COO Hazelton Joseph P

Director Kaye Jack exercised 30,000 shares at a strike of $1.33 and covered exercise/tax liability with 27,517 shares, increasing direct ownership by 4% to 59,649 units (SEC Form 4)

Director Herbst Seth exercised 25,000 shares at a strike of $0.97, increasing direct ownership by 16% to 180,759 units (SEC Form 4)

Director Kaye Jack converted options into 23,585 shares, increasing direct ownership by 70% to 57,166 units (SEC Form 4)

Director Tarnok Michael P. converted options into 23,585 shares, increasing direct ownership by 10% to 270,257 units (SEC Form 4)

Director Herbst Seth converted options into 23,585 shares, increasing direct ownership by 18% to 155,759 units (SEC Form 4)

Director Lucy Patrick K. converted options into 23,585 shares, increasing direct ownership by 87% to 50,759 units (SEC Form 4)

Chief Financial Officer Rawson Ping Wang was granted 20,776 shares, increasing direct ownership by 17% to 140,993 units (SEC Form 4)

Director Bose Arindam converted options into 23,585 shares, increasing direct ownership by 87% to 50,759 units (SEC Form 4)

Chief Operating Officer Hazelton Joseph P was granted 30,172 shares, increasing direct ownership by 30% to 129,340 units (SEC Form 4)